Proven prevention with powerful results:
99.7% remained HIV negative with DESCOVY®1,2

DISCOVER is the largest PrEP clinical trial, with over 5300 participants2,3

Data from a randomized, active-controlled, double-blind study of adult HIV-seronegative MSM and TGW (N=5387) using once-daily DESCOVY FOR PrEP® (n=2694) vs FTC/TDF (n=2693).1,2

DESCOVY FOR PrEP was noninferior to FTC/TDF through 96 weeks1,2

HIV incidence rate (DESCOVY vs FTC/TDF)

Primary endpoint analysis*: 0.16/100 PY vs 0.34/100 PY (IRR=0.47; CI: 0.19-1.15)

Baseline through 96-week analysis†: 0.16/100 PY vs 0.30/100 PY (IRR=0.54; CI: 0.23-1.26)

Study outcomes were similar across subgroups of age, race, gender identity, and baseline FTC/TDF use.

DESCOVY (n=2670)

99.7 %

FTC/TDF (n=2665)

99.4%

OF PARTICIPANTS REMAINED HIV NEGATIVE

AT PRIMARY ANALYSIS AND THROUGH 96 WEEKS

HIV prevention remained consistent over 144 weeks1,2,4

Analysis from baseline to over 144 weeks

  • HIV incidence rate: 0.13/100 PY

DESCOVY (n=2670)

99.6%

OF PARTICIPANTS REMAINED
HIV NEGATIVE OVER 144 WEEKS


*When 100% of participants reached Week 48 and >50% reached Week 96.

†When 100% of participants reached Week 96.

DESCOVY FOR PrEP was studied over 144 weeks in the DISCOVER Trial1,2,4

At entry and Q12W, participants were offered:

  • Adherence counseling
  • Prevention services (risk-reduction counseling, condoms)

Primary endpoint analysis (n=5335):

HIV incidence/100 PY when 100% of participants reached Week 48 and ≥50% reached Week 96. Secondary analysis was conducted when 100% of participants reached Week 96.

Analysis from baseline through 96 weeks (DESCOVY vs FTC/TDF):

  • Includes participants from both study arms in the 1:1 randomized, active-controlled, double-blind phase, from baseline through 96 weeks
    • Participants received either DESCOVY or FTC/TDF once daily

Analysis from baseline to ≥144 weeks (DESCOVY):

  • Includes participants who initiated DESCOVY at baseline, through 96 weeks in the double-blind phase, and voluntarily continued on DESCOVY during the unblinded, open-label extension phase for another 48 weeks or more
    • Participants received DESCOVY once daily

Participants selected for inclusion had significant risk of acquiring HIV2,5

Baseline
demographics

DESCOVY

(n=2694)

FTC/TDF

(n=2693)

Median age, years (IQR)

34 (28-43)
34 (28-44)

Sex/gender

Cis male

2649
2664

TGW

45
29

Race

White

2264
2247

Blackaa

240
234

Asian

113
120

Ethnicity

Hispanic or Latinx/o

635
683

Baseline
demographics

DESCOVY

(n=2694)

FTC/TDF

(n=2693)

Baseline HIV risk factors

≥2 condomless anal sex
partners, past 12 weeks

62%
60%

Rectal gonorrhea,
past 24 weeks

10%
10%

Rectal chlamydia,
past 24 weeks

13%
12%

Syphilis, past 24 weeks

9%
10%

Recreational drug use,
past 12 weeks

67%
67%

Binge drinkingbb

23%
22%

Taking FTC/TDF at baseline

17%
16%

baIncludes mixed Black race.

bb≥6 drinks ≥1 occasion, at least monthly.

FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; IQR=interquartile range; TGW=transgender women (who have sex with men).

Consider proven HIV prevention data from the largest clinical trial of PrEP.2,3

aIncludes mixed Black race.
b≥6 drinks ≥1 occasion, at least monthly.

CI=confidence interval; FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; IQR=interquartile range; IRR=incidence rate ratio; MSM=men who have sex with men; PY=person-years; Q12W=every 12 weeks; TGW=transgender women (who have sex with men).

Now that you’ve learned about the efficacy of DESCOVY vs FTC/TDF, there’s more to explore with DESCOVY.

Select a topic:

Review the safety profile for DESCOVY, including side effects (adverse events).

Discover the impact of DESCOVY on markers of renal function.

Learn more about once-daily dosing with DESCOVY.

See how to initiate DESCOVY.

Learn more about the co-pay program to help eligible patients receive DESCOVY.

Find answers to frequently asked questions (FAQs).